Source: Medovex Corp.
Medovex Corp. (NASDAQ: MDVX),
a developer of medical technology products, today announced that the
Company has hired Mr. Juan Davila as Director Sales & Marketing for
their DenerveX™ division of the business.
Mr. Davila, a Sales & Marketing leader with more than
over 20 years of experience in the Latin-American Market, is recognized
for his excellent record of business growth and market development of
new products in the highly competitive medical devices industry in Latin
America. Mr. Davila has a strong marketing and communication skills, in
both Spanish and Portuguese.
Davila will be developing and implementing an overall
corporate sales, marketing and strategy, directly engaging and managing
all future Medovex Distributors throughout the Americas, and translating
the company's business objectives into marketing strategies that drive
future revenue. In addition, Mr. Davila will also provide services to
help introduce the Medovex's DenerveX™ System to leading physicians and
medical professionals in Latin America.
"Juan drives market awareness and qualified sales leads
through a rare combination of medical technology savvy, customer,
distributor focus and persuasive communication," said Manfred Sablowski,
Medovex Senior Vice President Global Sales & Marketing. "His skill
set spans all aspects of Sales & Marketing, and we are thrilled to
be adding such a deep talent to the Medovex team."
Sablowski continues, "Juan Davila fits our mission to provide
a world-wide distribution channel for our DenerveX System, while
serving an important market segment in Latin America."
Prior to accepting this position, Davila established
successful his own consulting firm with focus on the Latin American
Healthcare Market and worked for Worldwide well known Medical Technology
Companies like Valleylab (former Tyco/U.S Surgical/Pfizer) as General
Manager Latin America which resulted in sales growth of 850% as well as
Howmedica (former Pfizer).
The Company's patented DenerveX™ System is intended to treat
Facet Joint Syndrome (FJS), a condition in which the joints in the back
of the spine degenerate and subsequently cause pain. Lower back pain is
the second most common cause of disability in the U.S. for adults.
Studies indicate that 10% of the U.S. adult population suffers from
lower back pain and that 31% of lower back pain is attributed to FJS
pain.
The DenerveX System consists of the DenerveX device, a single
use medical device and the DenerveX Pro-40 Power Generator, both
designed to be less invasive with faster recovery time than current
surgical treatment options. It consists of two procedures combined into
one device and is expected to provide for a longer lasting treatment
solution while offering potential savings to the health care system.
DenerveX is not yet commercially available.
DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.
About Medovex
Medovex was formed to acquire and develop a diversified
portfolio of potentially ground breaking medical technology products.
Criteria for selection include those products with potential for
significant improvement in the quality of patient care combined with
cost effectiveness. The Company's first pipeline product, the DenerveX
device, is intended to provide long lasting relief from pain associated
with facet joint syndrome at significantly less cost than currently
available options. To learn more about Medovex Corp., visit www.medovex.com
No comments:
Post a Comment